MetaCap

KORU Medical Systems Inc. (KRMD)

NASDAQ: KRMDHealth CareMedical/Dental InstrumentsUSD

3.19-0.25 (-7.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KRMD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$138.37M
EPS (TTM)
-$0.02
52-week range
2.86 – 6.61
Day range
3.17 – 3.48
Volume / Avg
320.88K / 223.45K
Beta
—

52-week range

$2.86$6.61

KRMD stock today

On Nov 20, KRMD ended the session at $3.19, shedding $0.25 (7.27%), versus the S&P 500's 3.70% decline. At this level, KRMD sits near the bottom of its 52-week range of $2.86 to $6.61: 51.7% below the high, set on Dec 24, 2025 and 11.5% above the low. KRMD is down 45.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 33.3%.

KORU Medical Systems has posted a net loss over the last twelve months (EPS of -$0.02), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About KORU Medical Systems

Company profile

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH).

Industry
Medical/Dental Instruments
CEO
Mr. Adam Kalbermatten
Headquarters
Mahwah, NJ
Employees
73

Financial highlights

Full financials

In fiscal 2025, KORU Medical Systems generated $41.1 million in revenue, up 22.2% from fiscal 2024, its 4th consecutive year of revenue growth. KORU Medical Systems reported a net loss of $2.6 million, compared with a loss of $6.1 million a year earlier. Gross margin was 62.3% (down from 63.4%) and operating margin -7.2%.

KORU Medical Systems annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$41.13M$33.65M$28.52M$27.90M$23.49M
Growth+22.23%+17.98%+2.23%+18.76%-2.84%
Net income$-2.64M$-6.07M$-13.74M$-8.66M$-4.56M
EPS (diluted)$-0.06$-0.13$-0.30$-0.19$-0.10

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$6.13+92.16%

  • Strong buy 0
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.50High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$0.00 vs $0.00

KRMD news

All KRMD news

KORU Medical Systems peers

Health Care sector
KRMD peer companies
CompanyPrice% ChgMarket capCompare
PYPDPolyPid Ltd.6.12-6.56%$129.29Mvs KRMD
STIMNeuronetics Inc.1.25+0.81%$120.60Mvs KRMD
LUNGPulmonx Corporation2.57-6.20%$111.93Mvs KRMD
APYXApyx Medical Corporation2.40+0.42%$101.10Mvs KRMD
ANIKAnika Therapeutics Inc.13.23-0.38%$177.22Mvs KRMD
NYXHNyxoah SA0.805-7.01%$81.98Mvs KRMD
UTMDUtah Medical Products Inc.69.49-2.07%$198.01Mvs KRMD
SKINSkinHealth Systems Inc. Class A11.77-3.13%$76.68Mvs KRMD

Indexes, lists and sector

KORU Medical Systems stock FAQ

What is KORU Medical Systems's stock price today?

KRMD last traded at $3.19 as of Nov 20, 4:00 PM EST, down 7.27% on the day. Prices are delayed at least 15 minutes.

Who is KORU Medical Systems's CEO?

Mr. Adam Kalbermatten is the chief executive officer of KORU Medical Systems Inc., which has about 73 employees.

What is the KRMD 52-week high?

The 52-week high for KRMD is $6.61 and the 52-week low is $2.86. The stock is currently 51.7% below its high.

Compare KRMD